News Updates
NEWS CENTER
Related News
There is currently no data available
Moderna sues Pfizer and other new coronavirus vaccines for infringement of its mRNA technology patent
Release Time：
2022-08-29
On August 26, the American biotechnology company Moderna sued American Pfizer Pharmaceuticals Co., Ltd. and German Biotech, accusing the new coronavirus vaccine jointly developed by the latter two infringing on Moderna's mRNA (messenger ribonucleic acid) technology patent. Pfizer and Biotech responded that they did not accept Moderna's accusations.
Moderna and Pfizer/BioNTech are the manufacturers of the two earliest and most widely used mRNA COVID-19 vaccines.
On August 26, the American biotechnology company Moderna sued American Pfizer Pharmaceuticals Co., Ltd. and German Biotech, accusing the new coronavirus vaccine jointly developed by the latter two infringing on Moderna's mRNA (messenger ribonucleic acid) technology patent. Pfizer and Biotech responded that they did not accept Moderna's accusations.
Moderna accuses two companies of infringing on its core technology patents. Screenshot of the company’s official website
According to information released by Moderna on its official website, the company believes that the new crown vaccines of Pfizer and German Biotech infringe the patents submitted by Moderna between 2010 and 2016 covering basic mRNA technology. Moderna pointed out that the two companies copied two key features of its patented technology and continued to use them without permission. These breakthrough technologies were critical to the development of Moderna's own COVID-19 vaccine, and Pfizer and BioNTech copied the technology without permission to make their own COVID-19 vaccines.
Moderna CEO Stéphane Bancel said the lawsuit was filed to protect the company's innovative mRNA technology platform, which it invested billions of dollars to create and patent in the 10 years before the coronavirus pandemic. . Moderna stated that it will seek to collect patent royalties based on vaccine sales after March 8, 2022, but charging this fee will exclude vaccine sales in some low- and middle-income countries.
Moderna said that out of the starting point of equitable global access to vaccines, the company promised in October 2020 not to enforce its relevant patents during the COVID-19 pandemic. However, starting from March 2022, the fight against the COVID-19 epidemic has entered a new stage. Vaccine supplies are no longer in short supply in many parts of the world. Moderna had expected that companies such as Pfizer and German Biotech would respect its intellectual property rights, but the above-mentioned companies did not do so. Moderna said the lawsuit against Pfizer will be filed in U.S. District Court in Massachusetts on Friday. Complaints against the German biotech company will be submitted to the Düsseldorf Regional Court in Germany.
In response, Pfizer said in a statement that it was surprised that Moderna filed a lawsuit. Pfizer's new crown vaccine is based on the patented mRNA technology of the German Biotech Company and was jointly developed by Pfizer and the German Biotech Company. Pfizer will "firmly safeguard its own rights and interests." The German Biotech Company also emphasized in its response that the company's technology is original and will vigorously defend all accusations of patent infringement. The company values and respects the valid and enforceable intellectual property rights of others and is confident in its intellectual property rights.
Reuters reported that Moderna's COVID-19 vaccine, its only commercial product at present, has brought in revenue of US$10.4 billion this year, while Pfizer's COVID-19 vaccine has brought it about US$22 billion in revenue. In December 2020, the U.S. Food and Drug Administration (FDA) approved emergency use authorizations for Pfizer and Moderna’s COVID-19 vaccines.
Source: People's Daily
More intellectual property information and services
Follow the official subscription account of [Shenxin Intellectual Property] on the code
Follow the official service account of [Shentrust Intellectual Property Service Platform] on the code
相关新闻
Telephone：
Telephone：+86-755-82566227、82566717、13751089600
Head Office：13 / F, Building 14, Longhua Science and Technology Innovation Center (Mission Hills), No. 8 Golf Avenue, Guanlan Street, Longhua District, Shenzhen
Head Office：
13 / F, Building 14, Longhua Science and Technology Innovation Center (Mission Hills), No. 8 Golf Avenue, Guanlan Street, Longhua District, Shenzhen
Subsidiary Company：2808, Block B2, Yuexiu Xinghui Junbo, No.18 Tazihu East Road, Jiangan District, Wuhan City, Hubei Province
Subsidiary Company：
2808, Block B2, Yuexiu Xinghui Junbo, No.18 Tazihu East Road, Jiangan District, Wuhan City, Hubei Province
Service Number
Subscription Number
Copyright ©2016 Shenzhen Shenkexin patent Agency Co., LTD All rights reserved | 粤ICP备2021174526号
Copyright ©2016 深圳市深可信专利代理有限公司 版权所有 | 粤ICP备2021174526号 SEO标签
Copyright ©2016 深圳市深可信专利代理有限公司 版权所有
